Sugi Predict

Sugi Predict / Compounds / SCHEMBL981022

SCHEMBL981022

SCHEMBL981022

CCOC(=O)c1c(C)n(-c2ccc(OC)cc2)c2ccc(OC(F)F)cc12

nearest known ligand 0.65

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ TP53 P04637 5/20 0.65
▸ MAPT P10636 4/20 0.63
▸ SMN1; SMN2 Q16637 3/20 0.60
▸ HTT P42858 3/20 0.60
▸ MAPK1 P28482 2/20 0.60
▸ HPGD P15428 2/20 0.60
▸ PKM P14618 1/20 0.60
▸ ALOX15 P16050 1/20 0.60
▸ TSHR P16473 1/20 0.60
▸ HSD17B10 Q99714 1/20 0.60
▸ MEN1 O00255 6/20 0.60
▸ KMT2A Q03164 6/20 0.60
▸ THRB P10828 2/20 0.60
▸ ATM Q13315 1/20 0.59
▸ POLB P06746 2/20 0.57
▸ KDM4E B2RXH2 1/20 0.56
▸ HIF1A Q16665 1/20 0.55
▸ NPSR1 Q6W5P4 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10095274 0.91 TP53 (0.55) TP53MAPTSMN1; SMN2HTTMAPK1
SCHEMBL12306765 0.88 KMT2A (0.57) TP53MAPTSMN1; SMN2HTTMAPK1
SCHEMBL980968 0.85 MAPT (0.82) TP53MAPTSMN1; SMN2HTTMAPK1
SCHEMBL29059242 0.83 MEN1 (0.63) TP53MAPTSMN1; SMN2HTTMAPK1
SCHEMBL10192266 0.80 TP53 (0.52) TP53MAPTSMN1; SMN2HTTMAPK1
SCHEMBL12489894 0.80 POLB (0.51) TP53MAPTSMN1; SMN2HTTMAPK1
SCHEMBL30875172 0.78 SMN1; SMN2 (0.76) TP53MAPTSMN1; SMN2HPGDTSHR
SCHEMBL9557007 0.78 SMN1; SMN2 (0.76) TP53MAPTSMN1; SMN2HPGDTSHR
SCHEMBL12334437 0.77 POLB (0.49) TP53MAPTSMN1; SMN2HTTMAPK1
SCHEMBL29059386 0.76 TP53 (0.58) TP53MAPTSMN1; SMN2HTTMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8927576-B2 HCV inhibitor and therapeutic agent combinations PTC Therpeutics, Inc. (US) 2015-01-06 — — US disclosed
US-8927576-B2 HCV inhibitor and therapeutic agent combinations PTC Therpeutics, Inc. (US) 2015-01-06 — — US disclosed
US-20120027721-A1 HCV Inhibitor and Therapeutic Agent Combinations PTC THERAPEUTICS, INC. (US) 2012-02-02 — — US disclosed
US-20120027721-A1 HCV Inhibitor and Therapeutic Agent Combinations PTC THERAPEUTICS, INC. (US) 2012-02-02 — — US disclosed
US-20120009142-A1 METHODS FOR TREATING HEPATITIS C PTC THERAPEUTICS, INC. (US) 2012-01-12 — — US disclosed
US-20120009142-A1 METHODS FOR TREATING HEPATITIS C PTC THERAPEUTICS, INC. (US) 2012-01-12 — — US disclosed
US-20120009142-A1 METHODS FOR TREATING HEPATITIS C PTC THERAPEUTICS, INC. (US) 2012-01-12 — — US disclosed
US-20110268698-A1 METHODS FOR TREATING HEPATITIS C PTC THERAPEUTICS, INC. (US) 2011-11-03 — — US disclosed
US-20110268698-A1 METHODS FOR TREATING HEPATITIS C PTC THERAPEUTICS, INC. (US) 2011-11-03 — — US disclosed
US-20110268698-A1 METHODS FOR TREATING HEPATITIS C PTC THERAPEUTICS, INC. (US) 2011-11-03 — — US disclosed
US-20070299069-A1 Methods for treating hepatitis C PTC THERAPEUTICS, INC. 2007-12-27 — — US disclosed
US-20070299069-A1 Methods for treating hepatitis C PTC THERAPEUTICS, INC. 2007-12-27 — — US disclosed
US-20070299069-A1 Methods for treating hepatitis C PTC THERAPEUTICS, INC. 2007-12-27 — — US disclosed
US-20070299068-A1 Methods for treating hepatitis C PTC THERAPEUTICS, INC. 2007-12-27 — — US disclosed
US-20070299068-A1 Methods for treating hepatitis C PTC THERAPEUTICS, INC. 2007-12-27 — — US disclosed
WO-2007084413-A2 METHODS FOR TREATING HEPATITIS C PTC THERAPEUTICS, INC. (US) 2007-07-26 — — WO disclosed
EP-1771169-A1 METHODS FOR TREATING HEPATITIS C PTC Therapeutics, Inc. (US) 2007-04-11 — — EP disclosed
US-20060223863-A1 Methods for treating Hepatitis C KARP GARY M 2006-10-05 — — US disclosed
US-20060189606-A1 Methods for treating hepatitis C PTC THERAPEUTICS, INC. 2006-08-24 — — US disclosed
WO-2006019831-A1 METHODS FOR TREATING HEPATITIS C PTC THERAPEUTICS, INC. (US) 2006-02-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070299068-A1 Methods for treating hepatitis C HAVCR2, EIF2AK2, MAVS TP53 1262/4885MAPT 4477/4885SMN1; SMN2 3609/4885
US-20110268698-A1 METHODS FOR TREATING HEPATITIS C HAVCR2, LIPC, HCCS TP53 1579/4885MAPT 3547/4885SMN1; SMN2 4206/4885
US-20120009142-A1 METHODS FOR TREATING HEPATITIS C OAT, HAVCR2, HCCS TP53 3022/4885MAPT 4416/4885SMN1; SMN2 4525/4885
US-20060189606-A1 Methods for treating hepatitis C HAVCR2, EIF2AK2, MAVS TP53 1262/4885MAPT 4477/4885SMN1; SMN2 3609/4885
US-20070299069-A1 Methods for treating hepatitis C HAVCR2, EIF2AK2, MAVS TP53 1262/4885MAPT 4477/4885SMN1; SMN2 3609/4885
US-20060223863-A1 Methods for treating Hepatitis C OAT, HAVCR2, HCCS TP53 3022/4885MAPT 4416/4885SMN1; SMN2 4525/4885
US-20120027721-A1 HCV Inhibitor and Therapeutic Agent Combinations HAVCR2, SERPINB1, ENPEP TP53 1710/4885MAPT 4044/4885SMN1; SMN2 4565/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.